SHP2 Inhibition Benefits Epidermal Growth Factor Receptor-mutated Non-Small Cell Lung Cancer Therapy

Author(s): Leiming Xia, Lu Wen, Siying Wang*

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 21 , Issue 11 , 2021

Become EABM
Become Reviewer
Call for Editor


EGFR-TKIs are confronted with big challenge of everlasting activated EGFR mutations which lack effective binding sites; this barrier is the dark side that largely limits the outcome of NSCLC patients in the clinic. Combination strategies show impressive anti-tumor efficacy that compared with EGFR-TKI mono-treatment, especially targeting both stem cells and non-stem cells. SHP2 (Src homology 2-containing phosphotyrosine phosphatase 2) plays an important role in regulating various malignant biology through hyper-activating intracellular pathways due to either overexpression or catalytical mutation. Some pathways, in which SHP2 was involved, were overlapped with EGFR downstream, and others were not subject to EGFR. Interestingly, SHP2 suppression was reported to destroy the stemness of cancer. Therefore, we hypothesize that SHP2 inhibitor might be a promising drug that could synergistically enhance or sensitize the anti-tumor efficacy of EGFR-TKIs in EGFR mutated NSCLC patients. Here, we summarized the mechanisms of SHP2 in regulating EGFR mutated NSCLC patients, and attempted to reveal the potential synergistic file://localhost/C/:Program%20Files%20(x86):Youdao:Dict: of SHP2 inhibitor combined with EGFR-TKIs.

Keywords: EGFR-TKIs, mutation, SHP2, drug resistence, inhibition, NSCLC.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Page: [1314 - 1321]
Pages: 8
DOI: 10.2174/1389557520666201127104104
Price: $95

Article Metrics

PDF: 25